RT Journal Article T1 Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis. A1 Zozaya, Néboa A1 Abdalla, Fernando A1 Alfonso Zamora, Santiago A1 Balea Filgueiras, Jesús A1 Carrascosa Carrillo, José Manuel A1 Delgado Sánchez, Olga A1 Dolz Sinisterra, Francisco A1 García-Ruiz, Antonio A1 Herranz Pinto, Pedro A1 Manfredi, Antonio A1 Martínez Olmos, José A1 Morales de Los Ríos Luna, Paloma A1 Puig, Lluis A1 Ros, Sandra A1 HIdalgo-Vega, Álvaro K1 MCDA K1 Psoriasis K1 bimekizumab K1 biologics K1 moderate-to-severe K1 multi-criteria decision analysis AB Multi-criteria decision analysis (MCDA) was proposed to surmount arbitrary clinical decisions in the field of biological therapies for psoriatic patients. At the same time, MCDA may further highlight the potential of bimekizumab for the treatment of moderate-to-severe psoriasis, compared to placebo, adalimumab, ustekinumab, secukinumab, and even ixekizumab and risankizumab. The EVIDEM framework was adapted to reflect relevant criteria for the assessment. Estimated values were obtained by means of an additive linear model combining weights and scores assigned by a multidisciplinary committee of 12 experts. Consistency and replicability were evaluated through an alternative weighting method and a re-test. Bimekizumab was assessed by the committee as an intervention with a positive value contribution for the treatment of moderate-to-severe psoriasis in comparison to any of the alternatives. The drug provides a substantial therapeutical benefits and improves the health results reported by the patients, as it combines a higher level of clearance, rapidity, and persistence with a similar safety and tolerability profile. Under a methodology with increasing use in the health field, bimekizumab was evaluated as a drug with a high added value for the treatment of moderate-to-severe psoriasis when compared to six different alternatives. YR 2022 FD 2022-04-25 LK http://hdl.handle.net/10668/19680 UL http://hdl.handle.net/10668/19680 LA en DS RISalud RD Apr 8, 2025